Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.1%. By the end of trading, Regeneron Pharmaceuticals rose $7.01 (2.1%) to $339.51 on average volume. Throughout the day, 1,162,824 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 935,600 shares. The stock ranged in a price between $327.02-$341.34 after having opened the day at $328.09 as compared to the previous trading day's close of $332.50. Other companies within the Drugs industry that increased today were: Fate Therapeutics ( FATE), up 28.8%, Dendreon ( DNDN), up 14.9%, Cara Therapeutics ( CARA), up 12.7% and DepoMed ( DEPO), up 11.4%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $33.1 billion and is part of the health care sector. Shares are up 20.8% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share.

On the negative front, RXi Pharmaceuticals ( RXII), down 11.7%, Synageva BioPharma ( GEVA), down 11.6%, NewLink Genetics ( NLNK), down 11.6% and Northwest Biotherapeutics ( NWBO), down 10.3% , were all laggards within the drugs industry with Merck ( MRK) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round